Welcome to our dedicated page for Glaukos news (Ticker: GKOS), a resource for investors and traders seeking the latest updates and insights on Glaukos stock.
Glaukos Corporation (GKOS) is a leader in ophthalmic medical technology, pioneering micro-invasive glaucoma surgery (MIGS) and transformative eye care solutions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access timely press releases covering product approvals, financial results, and research developments directly impacting glaucoma treatment paradigms. Our curated collection includes updates on therapeutic innovations, partnership announcements, and progress in addressing various stages of ocular disease.
Bookmark this page for streamlined access to Glaukos' latest achievements in medical device engineering and surgical techniques. Regularly updated content ensures you stay informed about developments influencing both patient care and the evolving ophthalmic technology landscape.
Glaukos Corporation (NYSE: GKOS) responded to the CMS 2022 Medicare Physician Fee Schedule Proposed Rule released on July 13, 2021. This rule updates reimbursement policies for cataract surgery combined with the insertion of an aqueous drainage device. Two new CPT codes (669X2 and 669X1) will replace existing codes, with Glaukos estimating the 2022 physician fee for 669X2 at approximately $565.23, an increase of $34.25 from the previous fee. The company expressed disappointment over these proposed fees and plans to engage with ophthalmic societies during the public comment period.
Glaukos Corporation (GKOS) has completed patient enrollment and randomization in its FDA Phase 3 clinical trials for the iDose® TR sustained-release travoprost implant. The two prospective trials involve 1,150 subjects across 89 sites, aiming to assess the safety and efficacy of the iDose TR compared to timolol for treating open-angle glaucoma. Successful trial results are expected to support NDA submission in 2022 and FDA approval in 2023, potentially enhancing patient adherence to glaucoma treatments.
Glaukos Corporation (NYSE: GKOS) has received regulatory approval from Australia's Therapeutic Goods Administration (TGA) for its PRESERFLO MicroShunt. This device is designed to reduce intraocular pressure in patients with primary open-angle glaucoma, providing an alternative to conventional surgeries. Glaukos plans to initiate commercial activities for the MicroShunt in late 2021, targeting a full launch by mid-2022, contingent on reimbursement. The company maintains exclusive commercialization rights for the MicroShunt across several key markets, including Australia and the Americas.
Glaukos Corporation (NYSE: GKOS), a leader in ophthalmic medical technology, will present at the William Blair 41st Annual Growth Stock Conference on June 2, 2021, at 4:40 p.m. CDT. The event will be available via live and archived webcast on their Investors website. Glaukos specializes in innovative therapies for glaucoma and corneal disorders, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) with devices like the iStent and its successors. The company's advancements aim to transform treatment paradigms in ophthalmology.
Glaukos Corporation (NYSE: GKOS) announced a development and commercialization license agreement with Santen Pharmaceutical for the PRESERFLO™ MicroShunt, replacing prior agreements. Glaukos gains exclusive commercialization rights in the U.S., Australia, Canada, and Latin America, along with full control over development activities. The MicroShunt, aimed at treating glaucoma, has a PMA application pending with the FDA. Santen will continue to manufacture the device. Financial terms of the agreement have not been disclosed.
Glaukos Corporation (GKOS) reported a 23% increase in net sales for Q1 2021, reaching $68.0 million, compared to $55.3 million in Q1 2020. Key segments included $53.7 million from glaucoma and $14.3 million from corneal health. The gross margin was approximately 76%, significantly up from 41% in the prior year. Operating expenses declined by 17% to $63.1 million, leading to a reduced net loss of $16.5 million or ($0.36) per share. The company projects Q2 2021 revenues between $70 million and $72 million.
Glaukos Corporation (NYSE: GKOS) announced an amended licensing agreement with Intratus, Inc. for the exclusive global license to develop and commercialize Intratus' non-invasive Eyelid Drug Delivery Platform, now including presbyopia treatments. This expands their existing agreement from 2019, which focused on dry eye disease and glaucoma. The platform offers a patient-friendly transdermal approach with promising early human study results. Financial terms were not disclosed, but the partnership aims to enhance Glaukos' portfolio in ophthalmic therapies.
Glaukos Corporation (NYSE: GKOS) will announce its Q1 2021 financial results on Wednesday, May 5, 2021, after market close. A conference call and webcast led by the management team will occur at 1:30 p.m. PDT (4:30 p.m. EDT) on the same day. Glaukos specializes in innovative therapies for glaucoma, corneal disorders, and retinal diseases, having pioneered Micro-Invasive Glaucoma Surgery (MIGS) since 2012 with devices like the iStent series. For participation details, please visit investors.glaukos.com.
Glaukos Corporation (NYSE: GKOS) launched two patient-centric initiatives for World Glaucoma Week, aimed at raising awareness of glaucoma. The initiatives include a global education campaign called “Making an iMPACT: Glaucoma Perspectives” featuring interviews with leading physicians and a glaucoma patient. Additionally, Glaukos will collaborate with U.S. eye care institutions to provide free glaucoma screenings. These efforts underline Glaukos' commitment to improving glaucoma treatment and patient education across the globe.
FAQ
What is the current stock price of Glaukos (GKOS)?
What is the market cap of Glaukos (GKOS)?
